Report of Seven Children With Undifferentiated Embryonal Sarcoma of the Liver

0
0
0

Report of Seven Children With Undifferentiated Embryonal Sarcoma of the Liver

Childhood liver tumors are rare—accounting for just 1–4% of all solid tumors in kids—and undifferentiated embryonal sarcoma of the liver (UESL) is even more uncommon, making up 9–15% of pediatric liver cancers. But for the families and doctors navigating this aggressive disease, every piece of research helps. A team from Beijing Tongren Hospital, Capital Medical University, recently shared insights from seven UESL cases to shed light on how to diagnose, treat, and manage this rare tumor.

What Is UESL?

UESL typically strikes kids between 6 and 10 years old (though the study’s patients ranged from 5 to 15), and there’s no clear gender difference. The first signs are often belly pain or swelling—without the jaundice (yellow skin) seen in other liver conditions. A key clue? Unlike many liver cancers, UESL doesn’t raise levels of alpha-fetoprotein (AFP), a blood marker doctors use to screen for liver tumors.

Why Diagnosis Is Tough

Before surgery, UESL is hard to spot. Doctors rely on tissue biopsies and immunohistochemistry (tests that look for specific proteins in cells) to confirm it. UESL cells usually test positive for proteins like vimentin (a connective tissue marker) and antitrypsin (AAT) but negative for AFP and S-100 (a brain tissue protein)—details that rule out other cancers.

Treatment: Surgery + Chemo Is Key

Historically, UESL had a grim prognosis: long-term survival was under 37%. But today, combining complete tumor removal (the most critical step) with chemotherapy has transformed outcomes. Some studies now report 5-year survival rates as high as 92–100%.

The Beijing team’s seven patients all had surgery: one needed emergency care after their tumor ruptured (they first got artery embolization to stop bleeding, then a liver resection once stable). Five started chemotherapy right after surgery; two waited until their tumor came back. Chemo drugs included cyclophosphamide, vincristine, and cisplatin—common in childhood cancer care.

The Big Finding: Recurrence Is Common, But Treatable

Nearly three-quarters (71%) of the kids had a recurrence. But here’s what mattered most:

  • Chemo timing: Kids who got chemo right after surgery had fewer repeat recurrences. Two patients who waited until relapse had tumors spread to multiple sites (liver, pelvis, lung) and relapsed 2–3 times.
  • Recurrence sites: The liver was the most common spot for tumors to come back, but some kids had spread to the lungs or abdomen. Even then, re-surgery and chemo worked—one child achieved complete remission (no cancer signs) after three relapses and four surgeries.

What Affects Prognosis?

Two factors stood out as red flags for poor outcomes:

  1. Tumor size: Three of four kids with tumors over 15cm died; all three with smaller tumors survived.
  2. Tumor rupture: Kids whose tumors broke open were far more likely to die (2 of 3) compared to those with intact tumors (all 4 survived)—a statistically significant difference (P=0.029).

Surprisingly, whether the tumor’s edges (margins) were clear after surgery didn’t affect survival in this group.

What This Means for Families and Doctors

For parents: If your child has belly pain or swelling and a normal AFP test, ask about UESL. Early surgery and chemo are critical.
For doctors: UESL should be on the radar for school-aged kids with liver tumors and normal AFP. Even with recurrence, aggressive treatment (re-surgery, chemo, sometimes radiation) can work.

The Bottom Line

UESL is rare, but research like this is narrowing the gap in care. The Beijing team’s study shows that while recurrence is common, combining surgery with timely chemotherapy can save lives. And for families, knowing that even relapses aren’t always hopeless is a lifeline.

This study was approved by the Beijing Tongren Hospital Ethics Committee and followed the Declaration of Helsinki. All patients and parents gave written consent. Funding came from the Beijing Municipal Administration of Hospitals’ “Climbing the Peak” Talent Plan (DFL20180201).

References:

  1. Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer. 1978;42:336–348.
  2. Shi Y, Rojas Y, Zhang W, et al. Characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver: a report from the National Cancer Database. Pediatr Blood Cancer. 2017;64:e26272.
  3. Putra J, Ornvold K. Undifferentiated embryonal sarcoma of the liver: a concise review. Arch Pathol Lab Med. 2015;139:269–273.
  4. Mathias MD, Ambati SR, Chou AJ, et al. A single-center experience with undifferentiated embryonal sarcoma of the liver. Pediatr Blood Cancer. 2016;63:2246–2248.

doi.org/10.1097/CM9.0000000000000429

Was this helpful?

0 / 0